烟草科技
2016-03-29 星期二
Product Technology:2017 ,13:86-96
ROULET Steve, MAINY Nelly, CHREA Christelle, MAGNANI Pierpaolo, WEITKUNAT Rolf, KALLISCHNIGG Gerd, RAMAZZOTTI Antonio. Pre-market studies from five countries in Asia and Europe to measure the adoption of the tobacco heating system (THS) in smokers[J]. 烟草科技, 2017 (13): 86-96.
ROULET Steve, MAINY Nelly, CHREA Christelle, MAGNANI Pierpaolo, WEITKUNAT Rolf, KALLISCHNIGG Gerd, RAMAZZOTTI Antonio. Pre-market studies from five countries in Asia and Europe to measure the adoption of the tobacco heating system (THS) in smokers[J]. Tobacco Science & Technology, 2017 (13): 86-96.

Pre-market studies from five countries in Asia and Europe to measure the adoption of the tobacco heating system (THS) in smokers
ROULET Steve1, MAINY Nelly2, CHREA Christelle2, MAGNANI Pierpaolo1, WEITKUNAT Rolf2, KALLISCHNIGG Gerd3, RAMAZZOTTI Antonio1
1. Philip Morris International Management S. A., Avenue de Rhodanie 50, 1007 Lausanne, Switzerland;
2. Philip Morris Products S. A., Quai Jeanrenaud 3, 2000 Neuchatel, Switzerland;
3. ARGUS-Statistics and Information Systems in Environment and Public Health GmbH, Berlin, Germany
摘要:
To predict potential public health impact of a candidate Modified Risk Tobacco Product (MRTP) requires pre-market information on how adult consumers actually use the product under close to real-world conditions. In this context, a Tobacco Heating System (THS) was assessed with regard to product adoption, use in conjunction with other tobacco products, and switching back to smoking cigarettes. Single group, four-week, consumer use studies were conducted between 2013 and 2015 in five countries (Germany, Italy, Japan, South Korea, and Switzerland). In total the analysis assessed how 2 809 adult smokers used THS based on participants' self-reported stick-by-stick consumption of THS and of conventional cigarettes (CC), using pre-defined product use categories (THS use, combined use, CC use). The results showed that:1) After four weeks, between 10% and 37% of the study participants switched either exclusively or predominantly to THS Tobacco Sticks, with highest adoption rates observed in Japan and South Korea. 2) Across countries, between 27% and 39% of the study participants used both cigarettes and THS during the study period. This combined use decreased over time, with dual users either returning to CC use or, to a lesser extent, transitioning completely to THS use. 3) Across countries, the daily average total tobacco product consumption (THS Tobacco Sticks plus CC) was lower than the self-reported consumption of cigarettes prior to entering the study. The introduction of the candidate MRTP THS in various countries would result in adoption by some adult smokers who would otherwise continue to smoke cigarettes,and with varying level of adoption, as suggested by the studies' results in Europe and Asia.
关键词:    Modified risk tobacco product    Heat-not-burn    Harm reduction    Consumer use study    Actual use study   
Pre-market studies from five countries in Asia and Europe to measure the adoption of the tobacco heating system (THS) in smokers
ROULET Steve1, MAINY Nelly2, CHREA Christelle2, MAGNANI Pierpaolo1, WEITKUNAT Rolf2, KALLISCHNIGG Gerd3, RAMAZZOTTI Antonio1
1. Philip Morris International Management S. A., Avenue de Rhodanie 50, 1007 Lausanne, Switzerland;
2. Philip Morris Products S. A., Quai Jeanrenaud 3, 2000 Neuchatel, Switzerland;
3. ARGUS-Statistics and Information Systems in Environment and Public Health GmbH, Berlin, Germany
Abstract:
To predict potential public health impact of a candidate Modified Risk Tobacco Product (MRTP) requires pre-market information on how adult consumers actually use the product under close to real-world conditions. In this context, a Tobacco Heating System (THS) was assessed with regard to product adoption, use in conjunction with other tobacco products, and switching back to smoking cigarettes. Single group, four-week, consumer use studies were conducted between 2013 and 2015 in five countries (Germany, Italy, Japan, South Korea, and Switzerland). In total the analysis assessed how 2 809 adult smokers used THS based on participants' self-reported stick-by-stick consumption of THS and of conventional cigarettes (CC), using pre-defined product use categories (THS use, combined use, CC use). The results showed that:1) After four weeks, between 10% and 37% of the study participants switched either exclusively or predominantly to THS Tobacco Sticks, with highest adoption rates observed in Japan and South Korea. 2) Across countries, between 27% and 39% of the study participants used both cigarettes and THS during the study period. This combined use decreased over time, with dual users either returning to CC use or, to a lesser extent, transitioning completely to THS use. 3) Across countries, the daily average total tobacco product consumption (THS Tobacco Sticks plus CC) was lower than the self-reported consumption of cigarettes prior to entering the study. The introduction of the candidate MRTP THS in various countries would result in adoption by some adult smokers who would otherwise continue to smoke cigarettes,and with varying level of adoption, as suggested by the studies' results in Europe and Asia.
Key words:    Modified risk tobacco product    Heat-not-burn    Harm reduction    Consumer use study    Actual use study   
收稿日期: 2017-07-25     修回日期: 2017-11-07
DOI: 10.16135/j.issn1002-0861.2017.0564
基金项目: The authors would like to thank Peter N Lee for providing the ISS data, review comments and suggestions for improvements on the revised version of the manuscript, which was funded by Philip Morris Products S.A.
通讯作者: ROULET Steve     Email:steve.roulet@pmi.com
作者简介:
相关功能
PDF(1055KB) Free
打印本文
HTML
把本文推荐给朋友
作者相关文章
ROULET Steve  在本刊中的所有文章
MAINY Nelly  在本刊中的所有文章
CHREA Christelle  在本刊中的所有文章
MAGNANI Pierpaolo  在本刊中的所有文章
WEITKUNAT Rolf  在本刊中的所有文章
KALLISCHNIGG Gerd  在本刊中的所有文章
RAMAZZOTTI Antonio  在本刊中的所有文章

参考文献:
[1] U.S. Department of Health and Human Services. The health consequences of smoking:a report of the surgeon general[R]. Atlanta, GA:U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004.
[2] U.S. Department of Health and Human Services. The health benefits of smoking cessation:a report of the surgeon general[R]. DHHS Publication No. (CDC) 90-8416. Atlanta:U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 1990.
[3] U.S. Department of Health and Human Services. How tobacco smoke causes disease:the biology and behavioral basis for smoking-attributable disease:a report of the Surgeon General[R]. Atlanta, GA:U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2010.
[4] Cummings K M. Programs and policies to discourage the use of tobacco products[J]. Oncogene, 2002, 21(48):7349-7364. DOI:10.1038/sj.onc.1205810.
[5] Rodu B, Godshall W T. Tobacco harm reduction:an alternative cessation strategy for inveterate smokers[J]. Harm Reduction Journal, 2006, 3:37. DOI:10.1186/1477-7517-3-37.
[6] Gottlieb S, Zeller M. A nicotine-focused framework for Public Health[J]. The New England Journal of Medicine, 2017, 377(12):1111-1114. DOI:10.1056/EJMp1707409.
[7] Stratton K, Shetty P, Wallace R, et al. Clearing the smoke:assessing the science base for tobacco harm reduction[M]. Washington, D.C.:National Academies Press, 2001.
[8] Smith M R, Clark B, Lüdicke F, et al. Evaluation of the tobacco heating system 2.2. Part 1:description of the system and the scientific assessment program[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):17-26. DOI:10.1016/j.yrtph.2016.07.006.
[9] Borgerding M, Klus H. Analysis of complex mixtures-cigarette smoke[J]. Experimental and Toxicologic Pathology, 2005, 57(S1):43-73. DOI:10.1016/j. etp.2005.05.010.
[10] Baker R R. Smoke generation inside a burning cigarette:modifying combustion to develop cigarettes that may be less hazardous to health[J]. Progress in Energy and Combustion Science, 2006, 32(4):373-385.
[11] Torikaiu K, Uwano Y, Nakamori T, et al. Study on tobacco components involved in the pyrolytic generation of selected smoke constituents[J]. Food and Chemical Toxicology, 2005, 43(4):559-568. DOI:10.1016/j. fct.2004.12.011.
[12] Oviedo A, Lebrun S, Kogel U, et al. Evaluation of the tobacco heating system 2.2. Part 6:90-day OECD 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects of a mentholated version compared with mentholated and non-mentholated cigarette smok[eJ]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):S93-S122. DOI:10.1016/j. yrtph.2016.11.004.
[13] Kogel U, Titz B, Schlage W K, et al. Evaluation of the tobacco heating system 2.2. Part 7:systems toxicological assessment of a mentholated version revealed reduced cellular and molecular exposure effects compared with mentholated and non-mentholated cigarette smoke[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):S123-S138. DOI:10.1016/j.yrtph.2016.11.001.
[14] Schaller J P, Pijnenburg J P, Ajithkumar A, et al. Evaluation of the tobacco heating system 2.2. Part 3:influence of the tobacco blend on the formation of harmful and potentially harmful constituents of the Tobacco Heating System 2.2 aerosol[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):S48-S58. DOI:10.1016/j.yrtph.2016.10.016.
[15] Schaller J P, Keller D, Poget L, et al. Evaluation of the tobacco heating system 2.2. Part 2:chemical composition, genotoxicity, cytotoxicity, and physical properties of the aerosol[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):S27-S47.
[16] Sewer A, Kogel U, Talikka M, et al. Evaluation of the tobacco heating system 2.2(THS2.2). Part 5:microRNA expression from a 90-day rat inhalation study indicates that exposure to THS2.2 aerosol causes reduced effects on lung tissue compared with cigarette smoke[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):S82-S92. DOI:10.1016/j.yrtph.2016.11.018.
[17] Wong E T, Kogel U, Veljkovic E, et al. Evaluation of the tobacco heating system 2.2. Part 4:90-day OECD 413 rat inhalation study with systems toxicology endpoints demonstrates reduced exposure effects compared with cigarette smoke[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):S59-S81. DOI:10.1016/j. yrtph.2016.10.015.
[18] Martin F, Talikka M, Ivanov N V, et al. Evaluation of the tobacco heating system 2.2. Part 9:application of systems pharmacology to identify exposure response markers in peripheral blood of smokers switching to THS2.2[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):S151-S157. DOI:10.1016/j.yrtph. 2016.11. 011.
[19] Haziza C, de la Bourdonnaye G, Skiada D, et al. Evaluation of the tobacco heating system 2.2. Part 8:5-day randomized reduced exposure clinical study in Poland[J]. Regulatory Toxicology and Pharmacology, 2016, 81(S2):139-150. DOI:10.1016/j.rtph.2016.11.003.
[20] Hatsukami D K, Giovino G A, Eissenberg T, et al. Methods to assess potential reduced exposure products[J]. Nicotine & Tobacco Research, 2005, 7(6):827-844. DOI:10.1080/14622200500266015.
[21] Hatsukami D K, Biener L, Leischow S J, et al. Tobacco and nicotine product testing[J]. Nicotine & Tobacco Research, 2012, 14(1):7-17. DOI:10.1093/ntr/ntr027.
[22] IOM (Institute of Medicine). Scientific standards for studies on modified risk tobacco products[M]. Washington, D.C.:The National Academies Press, 2012.
[23] U.S. Department of Health and Human Services Food and Drug Administration Center for Tobacco Products. Guidance for industry-Modified risk tobacco product applications-Draft Guidance[EB/OL]. (2012-03)[2017-07-11]. https://www.fda.gov/downloads/TobaccoProducts/GuidanceComplianceRegulatoryInformation/UCM297751.pdf.
[24] FDA (Food and Drug Administration). Guidance for industry-Label comprehension studies for nonprescription drug products[R]. Silver Spring, MD:U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2010.
[25] Leonard-Segal A, Shay L E, Shetty D, et al. Unique role of consumer studies in nonprescription drug development[J]. Journal of the American Pharmacists Association, 2009, 49(5):670-673. DOI:10.1331/JAPhA.2009.08068.
[26] Brass E P, Shay L E, Leonard-Segal A. Analysis of multiple end points in consumer research in support of switching drugs from prescription to over-the-counter status:the concept of end-point hierarchies[J]. Clinical Pharmacology & Therapeutics, 2009, 85(4):369-374. DOI:10.1038/clpt.2008.254.
[27] Raymond E G, Chen P L, Dalebout S M."Actual use" study of emergency contraceptive pills provided in a simulated over-the-counter manner[J]. Obstetrics & Gynecology, 2003, 102(1):17-23.
[28] Melin J M, Struble W E, Tipping R W, et al. A consumer use study of over-the-counter lovastatin (CUSTOM)[J]. The American Journal of Cardiology, 2004, 94(10):1243-1248. DOI:10.1016/j.amjcard.2004.08.007.
[29] U.S. Food and Drug Administration (FDA). Philip Morris products S.A. modified risk tobacco product (MRTP) applications[EB/OL].[2017-07-11]. https://www.fda.gov/TobaccoProducts/Labeling/MarketingandAdvertising/ucm546281.htm.
[30] Lawless H T, Heymann H. Consumer field tests and questionnaire design[M]//Lawless H T, Heymann H. Sensory Evaluation of Food:Principles and Practices. 2nd ed. New York, NY:Springer, 2010:349-378.
[31] Shiffman S, Stone A A, Hufford M R. Ecological momentary assessment[J]. Annual Review of Clinical Psychology, 2008, 4:1-32.
[32] Pearson J L, Smiley S L, Rubin L F, et al. The moment study:protocol for a mixed method observational cohort study of the Alternative Nicotine Delivery Systems (ANDS) initiation process among adult cigarette smokers[J]. BMJ Open, 2016, 6(4):e011717. DOI:10.1136/bmjopen-2016-011717.
[33] Pearson J L, Elmasry H, Das B, et al. Comparison of ecological momentary assessment versus direct measurement of E-Cigarette use with a bluetooth-enabled E-Cigarette:a pilot study[J]. JMIR Research Protocols, 2017, 6(5):e84. DOI:10.2196/resprot.6501.
[34] Ng M, Freeman M K, Fleming T D, et al. Smoking prevalence and cigarette consumption in 187 countries, 1980-2012[J]. JAMA, 2014, 311(2):183-192. DOI:10.1001/jama.2013.284692.
[35] Troost J P, Barondess D A, Storr C L, et al. An updated global picture of cigarette smoking persistence among adults[J]. Journal of Epidemiology and Global Health, 2012, 2(3):135-144. DOI:10.1016/j.jegh.2012.06.003.
[36] Ansara D L, Arnold F, Kishor S, et al. Tobacco use by men and women in 49 countries with demographic and health surveys[R]. DHS Comparative Reports No. 31. Calverton, Maryland, USA:ICF International, 2013.
[37] Pampel F C. Divergent patterns of smoking across high-income nations[M]//Crimmins E M, Preston S H, Cohen B. International Differences in Mortality at Older Ages:Dimensions and Sources. Washington, D.C., USA:The National Academies Press, 2010:132-163.
[38] Forey B, Hamling J, Hamling J, et al. International smoking statistics:a collection of historical data from 30 economically developed countries[EB/OL]. (2016-12-09)[2017-04-11]. http://www.pnlee.co.uk/ISS3.htm.
[39] Russell M A. Low-tar medium-nicotine cigarettes:a new approach to safer smoking[J]. British Medical Journal, 1976, 1(6023):1430-1433.
[40] Cobb N K, Abrams D B. The FDA, e-cigarettes, and the demise of combusted tobacco[J]. The New England Journal of Medicine, 2014, 371(16):1469-1471. DOI:10.1056/NEJMp1408448.
[41] Levy D T, Cummings K M, Villanti A C, et al. A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products[J]. Addiction, 2017, 112(1):8-17. DOI:10.1111/add.13394.
[42] Weitkunat R, Coggins C R E, Sponsiello-Wang Z, et al. Assessment of cigarette smoking in epidemiologic studies[J]. Beiträge zur Tabakforschung International, 2013, 25(7):638-648.
[43] IARC (International Agency for Research on Cancer). Measuring tobacco use behaviors[M]//International Agency for Research on Cancer, World Health Organization. IARC handbook of cancer prevention volume 12:Methods for evaluating tobacco control policies. Lyon:International Agency for Research on Cancer, 2009:75-105.
[44] Burris J L, Carpenter M J, Wahlquist A E, et al. Brief, instructional smokeless tobacco use among cigarette smokers who do not intend to quit:a pilot randomized clinical trial[J]. Nicotine & Tobacco Research, 2014, 16(4):397-405. DOI:10.1093/ntr/ntt161.
[45] Islami F, Stoklosa M, Drope J, et al. Global and regional patterns of tobacco smoking and tobacco control policies[J]. European Urology Focus, 2015, 1(1):3-16. DOI:10.1016/j.euf.2014.10.001.
[46] Pepper J K, Emery S L, Ribisl K M, et al. How risky is it to use e-cigarettes? Smokers' beliefs about their health risks from using novel and traditional tobacco products[J]. Journal of Behavioral Medicine, 2015, 38(2):318-326. DOI:10.1007/s10865-014-9605-2.
[47] Polosa R, Caponnetto P, Morjaria J B, et al. Effect of an electronic nicotine delivery device (e-Cigarette) on smoking reduction and cessation:a prospective 6-month pilot study[J]. BMC Public Health, 2011, 11:786. DOI:10.1186/1471-2458-11-786.
[48] Burris J L, Wahlquist A E, Alberg A J, et al. A longitudinal, naturalistic study of U.S. smokers'trial and adoption of snus[J]. Addictive Behaviors, 2016, 63:82-88. DOI:10.1016/j.addbeh.2016.07.008.
 烟草科技

版权所有:本网站由国家烟草专卖局科教司主管、中国烟草总公司郑州烟草研究院主办

中国烟草科技信息中心承办 所有数据不得复制    豫ICP备05011121号

Email:tst@tobaccoinfo.com.cn